Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Maternal Blood Test Detects Pre-Eclampsia Risk Before Symptoms Develop

By LabMedica International staff writers
Posted on 19 Nov 2025

Pre-eclampsia remains one of the most dangerous pregnancy complications, yet its cause is difficult to pinpoint because the disorder develops silently and is challenging to study. More...

A major obstacle has been identifying early molecular signals that warn of risk before symptoms appear. Researchers have now discovered that ancient viral DNA embedded in the human genome helps control a placenta-related gene that, when overexpressed, triggers key features of pre-eclampsia, pointing to a potential early biomarker for the condition.

In research led by the Max Delbrück Center (Berlin, Germany) and the University of Bath (Bath, England), the team used advanced deep-learning tools and biological assays to investigate how endogenous viral DNA fragments regulate placental gene expression. The method focused on A100 Beast, a deep-learning model created in the Mobile DNA Lab at the Max Delbrück Center.

By training the AI model to interpret DNA “like language,” researchers classified regulatory sequences across species and uncovered previously overlooked enhancers — many derived from ancient viruses. In placental genomes, the model identified a cluster of ERV3-MLT1 viral enhancers that appeared unusually active. Follow-up analyses confirmed 87 virus-derived enhancers in human placental tissue, boosting nine genes commonly dysregulated in pre-eclampsia.

Experimental work then focused on one gene in particular: EPS8L1, a previously unstudied gene expressed in trophoblasts, the early placental cells essential for implantation and placental formation. Functional studies exposed the gene’s role in disease: overexpressing EPS8L1 in placental cell cultures induced hallmark features of pre-eclampsia, including diminished trophoblast invasion, impaired blood vessel formation, and oxidative stress–related cell damage. Complete knockout of the gene caused cell death, confirming its necessity for normal placental function.

A key practical finding was that a secreted form of EPS8L1 is detectable in maternal blood, where its levels tracked with known pre-eclampsia biomarkers. The gene was consistently upregulated across all study cohorts and did not appear in other pregnancy complications, suggesting it could serve as a specific early-onset biomarker for pre-eclampsia if validated in larger clinical studies.

In addition to its diagnostic potential, the research, published in Genome Biology, highlights the deep evolutionary roots of this regulatory system. The ERV3-MLT1 viral DNA driving EPS8L1 expression originated more than 100 million years ago in a common ancestor of primates and rodents, illustrating how ancient viral infections still shape modern human biology.

“These findings connect a deep evolutionary process to a very modern clinical problem and point to a potential biomarker to detect pre-eclampsia risk before symptoms develop,” said Professor Zsuzsanna Izsvák, group leader and co-corresponding author.

Related Links:
Max Delbrück Center
University of Bath


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.